Stock Analysis, Dividends, Split History

CFI / Culp, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price32.95
Volume10,400.00
Market Cap ($M)410.24
Enterprise Value ($M)389.01
Book Value ($M)161.49
Book Value / Share12.90
Price / Book2.51
NCAV ($M)61.07
NCAV / Share4.88
Price / NCAV5.30
Share Statistics
Common Shares Outstanding 12,450,276
Common Stock Shares Outstanding 12,450,276
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.13
Return on Assets (ROA)0.10
Return on Equity (ROE)0.14
Balance Sheet (mrq) ($M)
Assets226.37
Liabilities60.34
Quick Ratio1.82
Current Ratio3.33
Income Statement (mra) ($M)
Sales Revenue Net323,725,000.00
Operating Income27.46
Net Income20.88
Earnings Per Share Basic1.68
Earnings Per Share Diluted1.65
Cash Flow Statement (mra) ($M)
Cash From Operations27.47
Cash from Investing-15.11
Cash from Financing-15.11
Identifiers and Descriptors
CUSIP230215105
Central Index Key (CIK)723603

Split History

Stock splits are used by Culp, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Culp, Inc. (CULP) CEO Frank Saxon on Q1 2019 Results - Earnings Call Transcript

2018-08-30 seekingalpha
Good day, and welcome to the Culp’s First Quarter 2019 Earnings Conference Call. Today's call is being recorded. At this time, for opening remarks and introductions, I'd like to turn the conference over to Ms. Dru Anderson. Please go ahead ma’am.

Casper, a Web Pioneer, to Open 200 Stores - WSJ

2018-08-09 wsj
Online mattress seller Casper Sleep Inc. plans to open 200 of its own stores in the next three years, expanding across North America to stave off competition from dozens of internet copycats. (4-0)

Bear of the Day - BlackRock Capital Investment Corp.

2018-06-29 zacks
BlackRock Capital (BKCC - Free Report) is a class of investment known as a “Business Development Company” (BDC) which were created by a 1980 amendment to the Investment Company Act of 1940. BDCs are unregulated closed-end investment companies that invest in small and mid-sized businesses. They are similar to Private Equity or Venture Capital Funds, except that they are usually traded on an exchange like a stock, instead of being open only to very wealthy investors. (7-1)

Bear of the Day: MercadoLibre (MELI)

2018-06-28 zacks
MercardoLibre, Inc. (MELI - Free Report) is getting hit by increased competition, especially from Amazon, in the online marketplace. This Zacks Rank #5 (Strong Sell) is expected to see an 88% decline in earnings in 2018. MercardoLibre is Latin America's leading e-commerce company with its websites MercadoLibre.com and MercadoPago.com. Big Miss in the Fiscal First Quarter On May 9, MercadoLibre reported first quarter results but missed on the Zacks Consensus for the 4th consecutive quarter. (23-1)

Bear of the Day: Ichor Holdings (ICHR)

2018-06-27 zacks
Many of the market’s top semiconductor companies have watched their momentum run out of steam in recent months, and that means investors might want to think about reducing their exposure to chip stocks, especially those that have been underperforming lately. (5-0)

CUSIP: 230215105